Boston, MACIK 16870784 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
38 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Cullinan Therapeutics Inc | 7.65M | $79.16M | 9.1% | 0 | Held |
| 2 | Madrigal Pharmaceuticals Inc | 96.8K | $56.36M | 6.4% | −3.6K | Reduced |
| 3 | Liquidia Corporation | 1.40M | $48.32M | 5.5% | +1.20M | Added |
| 4 | Trevi Therapeutics Inc |
| 3.29M |
| $41.15M |
| 4.7% |
| −119.9K |
| Reduced |
| 5 | Edgewise Therapeutics Inc | 1.66M | $41.08M | 4.7% | −65.5K | Reduced |
| 6 | Revolution Medicines Inc | 505.7K | $40.28M | 4.6% | +189.9K | Added |
| 7 | Agios Pharmaceuticals Inc | 1.30M | $35.48M | 4.1% | +1.30M | New |
| 8 | Uniqure NV | 1.38M | $33.06M | 3.8% | +1.38M | New |
| 9 | Ptc Therapeutics Inc | 430.0K | $32.66M | 3.7% | −8.5K | Reduced |
| 10 | Syndax Pharmaceuticals Inc | 1.34M | $28.11M | 3.2% | −38.0K | Reduced |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio